Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Elevated Glucose Associated with Undetected Heart Damage

By LabMedica International staff writers
Posted on 23 Feb 2012
Elevated levels of glycated hemoglobin (HbA1) are associated with minute levels of the protein troponin T (cTnT), a blood marker for heart damage. More...


A high-sensitivity blood test has been used to detect levels of cTnT showed that the concentrations were tenfold lower than those found in patients diagnosed with a heart attack.

Scientists at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA) tested the hypothesis that in persons without clinically evident chronic heart disease (CHD) or heart failure, chronic hyperglycemia, assessed by HbA1c, would be independently associated with subclinical myocardial injury measured by elevated cTnT. The cTnT was measured using a novel high-sensitivity assay; Elecsys Troponin T (hs-cTnT) with a lower limit of detection of 3.0 ng/L. Elevated hs-cTnT was defined as levels above 4 ng/L in a healthy subpopulation, which were 20 to 70 year old.

The scientists followed 9,662 participants from the Atherosclerosis Risk in Communities (ARIC) study. None of the participants had coronary heart disease or history of heart failure. Higher levels of HbA1c were associated in a graded fashion with elevated levels of high-sensitivity cTnT. This relationship was present at HbA1c levels even below the threshold used to diagnose diabetes. Using conventional tests, troponin T can be detected in 0.7% of the population and is associated with heart attacks and death. With the high-sensitivity Elecsys Troponin T test (Roche Diagnostics; Indianapolis, IN, USA) low levels of troponin were found in 66% of the study population.

Jonathan Rubin, MD, a lead author of the study, said, "Our study hints at other potential pathways by which diabetes and elevated glucose are associated with heart disease. Mainly, glucose might not only be related to increased atherosclerosis, but potentially elevated glucose levels may directly damage cardiac muscle." The study was published on January 31, 2012, in the Journal of the American College of Cardiology.

Related Links:

Johns Hopkins Bloomberg School of Public Health
Roche Diagnostics



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.